Abstracts Archive - Page 337 of 2607 - ACR Meeting Abstracts

Abstract Number: 0455 • ACR Convergence 2024
Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project
Ikwinder Preet Kaur¹, Gurjit Kaeley², Cristine Arcilla³, Ngun Par⁴ and Thway Myant⁵, ¹University of Florida College of Medicine, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida Jacksonville, Jacksonville, FL, ⁴University of Florida Jacksonville Physicians Inc, Jacksonville, ⁵UF Jacksonville, Mia, FL
Background/Purpose: RMD patients are at increased risk of adverse pregnancy outcomes either from the active disease itself or the use of immunosuppressants incompatible with pregnancy.…
Abstract Number: 0475 • ACR Convergence 2024
Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Cilia Peralta Ginés¹², Carolina Diez Morrondo¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno Martinez-Losa²³, Ana Urruticoechea-Arana²⁴, Sergi Ordoñez²⁵, Carmen González Montagut²⁶, Andrea García-Valle²⁷, Juan Ramón De Dios²⁸, Patricia Carreira²⁹, Tomás Vázquez Rodríguez³⁰, Delia Fernández-Lozano³¹, Ignacio Brana Abascal³², Rafael Benito Melero-Gonzalez³³, Emilio Giner³⁴, Virginia Ruiz Esquide³⁵, Clara Ventin Rodriguez³⁶, Marina Rodriguez³⁷, Pablo Andújar-Brazal³⁸, Julia Fernandez Melon³⁹, Lilian M. López-Núñez⁴⁰, JOSE RAMON LAMUA RIAZUELO⁴¹, Carlos Fernández Díaz⁴², Javier Loricera⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Hospital de Leon, León, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ²⁵Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁶Hospital Universitario de Valladolid, Valladolid, Spain, ²⁷Hospital General Río Carrión, Palencia, Spain, ²⁸Osakidetza, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ³⁰Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ³²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³³CHU Ourense, O Carballino, Spain, ³⁴Hospital Royo Villanova, Teruel, Spain, ³⁵Hospital Clinic Barcelona, Barcelona, Spain, ³⁶Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁷Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁸Hospital Universitario Doctor Peset, Valencia, Spain, ³⁹Hospital Son Espases, Palma, Spain, ⁴⁰Hospital Universitari Son Llàtzer, Palma, Spain, ⁴¹Hospital Universitario del Henares, Madrid, Spain, ⁴²Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
Abstract Number: 0429 • ACR Convergence 2024
Exploring the Impact of Autoimmune Rheumatic Diseases on Human Milk Macronutrient Composition
Rashmi Dhital¹, Kerri Bertrand², Essi Heinonen³ and Christina Chambers⁴, ¹UC San Diego, Brentwood, TN, ²UC San Diego, San Diego, CA, ³UC San Diego, La Jolla, CA; Karolinska Institutet, Stockholm, Sweden, San Diego, CA, ⁴University of California, San Diego, La Jolla, CA
Background/Purpose: Systemic inflammation in autoimmune rheumatic diseases (ARDs) may alter human milk composition, akin to changes observed in other inflammatory states, indirectly impacting infant health,…
Abstract Number: 0469 • ACR Convergence 2024
SCORE2 Is Superior to SCORE in Predicting the Presence of Carotid Plaques and Intima-media Thickness in Rheumatoid Arthritis Patients: A Cross-sectional Study with Carotid Ultrasound
Cristina Campos Fernández¹, Jorge Juan Fragío Gil², Roxana González Mazario³, Pablo Martínez Calabuig⁴, Laura Salvador Maicas⁵, Mireia Lucía Sanmartín Martínez⁶, Iván Jesús Lorente Betanzos⁶, Clara Molina Almela⁶, juan José Lerma Garrido⁷, Amalia Rueda³ and Jose A Román-Ivorra⁸, ¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ²Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ³Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁴HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ⁵Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ⁶Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) escalates the risk of premature mortality, predominantly through cardiovascular diseases. Although SCORE and its updated version, SCORE2, are employed to assess…
Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Bas Dijkshoorn¹, Sreen Mohamed², Romy Hansildaar², Henk Everaars³, Geoffrey Mooij³, Luuk Hopman³, Paul Knaapen³, Lourens Robbers³ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
Abstract Number: 0368 • ACR Convergence 2024
Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
Marc Scherlinger¹, Jean-Francois Kleinmann¹, Antonin Folliasson², Marianne Riviere³, Raphaelle Rybak⁴, Sabine Malivoir⁵, Jean-François Viallard⁶, Estibaliz Lazaro⁷, Christophe Richez⁸, Irene Machelart⁹, Nadine Magy-Bertrand¹⁰, Audrey Gorse¹¹, Gilles Blaison¹², Julien Campagne¹³, Benjamin Dervieux¹⁴, Thomas Moulinet¹⁵, Roland Jaussaud¹⁶, Pascal Roblot¹⁷, Mathieu Puyade¹⁷, Amélie Servettaz¹⁸, Pauline Orquevaux¹⁸, Julie le Scanff¹⁹, DANIEL WENDLING²⁰, Marc Andre²¹, Ludovic Trefond²¹, Perrine SMETS²², Nicolas Baillet²³, Christophe Deligny²⁴, Xavier Mariette²⁵, ARNAUD HOT²⁶, Emmanuelle David²⁷, Laurent Perard²⁸, Estelle Jean²⁹, Sarah Permal³⁰, Denis WAHL³¹, Christian Agard³², François Chasset³³, Baptiste Hervier³⁴, Pasquer Ronan², Mickael Martin¹⁷, Ludivine Lebourg³⁵, Frederic Renou³⁶, Loic Raffray³⁶, Elisabeth Diot³⁷, Cecile Fermont³⁸, Thierry Martin³⁹, Anne-Sophie Korganow³⁹, Jacques-Eric Gottenberg⁴⁰, Jean Sibilia⁴¹ and Zahir Amoura⁴², ¹Strasbourg University Hospital - National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ²Hometrix Health, Paris, France, ³Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Metz, France, ⁴Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Paris, France, ⁵APHP Pitié Salpêtrière - National reference center for autoimmune disease, Internal Medicine, Paris, France, ⁶CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹CH de Bayonne - Competence center for autoimmune diseases, Internal Medicine, Bayonne, France, ¹⁰CHU de Besancon - Competence center for autoimmune diseases, Internal Medicine, Besançon, France, ¹¹CH de Chambery - Competence center for autoimmune diseases, Internal Medicine, Chambery, France, ¹²CH de Colmar - Competence center for autoimmune diseases, Internal Medicine, Colmar, France, ¹³Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹⁴CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁵CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁶CHU de Nancy - Competence center for autoimmune diseases, Internal Medicine, Nancy, France, ¹⁷CHU de Poitiers - Competence center for autoimmune diseases, Internal Medicine, Poitiers, France, ¹⁸CHU de Reims - Competence center for autoimmune diseases, Internal Medicine, Reims, France, ¹⁹CH - Competence center for autoimmune diseases, Internal Medicine, Villefranche-sur-Saone, France, ²⁰University Hospital, Besançon, France, ²¹CHU de Clermont-Ferrand - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²²Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²³CH de Basse-Terre - Competence center for autoimmune diseases, Internal Medicine, Basse-Terre, France, ²⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique, ²⁵Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ²⁶Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ²⁷HCL - Croix Rousse, Internal Medicine, Lyon, France, ²⁸Hopital Saint-Joseph, Internal Medicine, Lyon, France, ²⁹APHM - La Timone, Internal Medicine, Marseille, France, ³⁰CH Mayotte - CH Wallis-et-Futuna, Internal Medicine, Mamoudzou, Mayotte, ³¹Lorraine University, Nancy, France, ³²CHU de Nantes - National reference center for autoimmune disease, Internal Medicine, Nantes, France, ³³Dermatology, Hôpital Tenon, Paris, France, ³⁴APHP Saint-Louis - National reference center for autoimmune disease, Internal Medicine, Paris, France, ³⁵CHU de Rouen, Internal Medicine, Rouen, France, ³⁶CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ³⁷CHU de Tours - Competence center for autoimmune diseases, Internal Medicine, Tours, France, ³⁸CH de Valence - Competence center for autoimmune diseases, Internal Medicine, Valence, France, ³⁹Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, ⁴⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁴¹Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ⁴²French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Systemic Lupus Erythematosus (SLE) features unpredictable disease activity fluctuations, making flare hard to detect and significantly impairing quality of life. This highlights the need…
Abstract Number: 0476 • ACR Convergence 2024
Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Alejandro Valero Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, María Martín López⁶, Santos Castañeda⁷, Jesús Loarce⁸, César Antonio Egües Dubuc⁹, Natalia Mena Vázquez¹⁰, Carmen Carrasco-Cubero¹¹, Carolina Perez-Garcia¹², Juan M Blanco Madrigal¹³, Nuria Vegas Revenga¹⁴, Lorena Pérez Albadalejo¹⁵, Rafaela Ortega-Castro¹⁶, Desiree Palma¹⁷, Ana Fernández-Ortiz¹⁸, Maria López Lasanta¹⁹, Marta Garijo Bufort²⁰, Ivette Casafont-Sole²¹, Andrea García-Valle²², Maria Paz Martinez-Vidal²³, Bryan Josué Flores Robles²⁴, EVELIN CERVANTES PEREZ²⁵, Ignacio Brana Abascal²⁶, Sara María Rojas Herrera²⁷, Juan Camilo Sarmiento-Monroy²⁸, Virginia Ruiz-Esquide²⁹, JOSE RAMON LAMUA RIAZUELO³⁰, Uxue Astigarraga-Urquia³¹, Diego Ferrer³² and Ricardo Blanco-Alonso³³, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Zumarraga Hospital, Zumarraga, Spain, ⁴Hospital de Jeréz de la Frontera, Cadiz, Spain, ⁵CHU Ourense, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, ¹⁰IBIMA, Málaga, Andalucia, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, ¹⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁵Hospital Universitario de Jaén, Jaén, Spain, ¹⁶Hospital Reina Sofía, Cordoba, Andalucia, Spain, ¹⁷Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁹Hospital Vall d�Hebron, Barcelona, Spain, ²⁰Hospital de Sagunto, Valencia, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²²Hospital General Río Carrión, Palencia, Spain, ²³Hospital San Juan de Alicante, Alicante, Spain, ²⁴Hospital San Pedro, Logroño, Spain, ²⁵Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²⁷Hospital de Mérida, Badajoz, Spain, ²⁸Hospital Clínic Barcelona, Barcelona, Spain, ²⁹Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰Hospital Universitario del Henares, Madrid, Spain, ³¹Hospital Universitario de Navarra, Pamplona, Spain, ³²Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
Abstract Number: 0477 • ACR Convergence 2024
The Global Prevalence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Hari Prasanna¹, Charles Inderjeeth², Johannes Nossent³ and KHALID ALMUTAIRI⁴, ¹University of Western Australia, Perth, Western Australia, Australia, ²SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia, ³University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ⁴The University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of rheumatoid arthritis (RA) that severely impacts the health outcomes of RA patients. Despite this, the…
Abstract Number: 0465 • ACR Convergence 2024
Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
Monique Bastidas¹, Lythou Yeo¹, Susie Magpantay¹, Judah Scott¹, Mike Zikry¹, Wayne Galdamez¹, Jane Yang² and Kelly Chun¹, ¹Labcorp, Calabasas, CA, ²LabCorp, Weston, MA
Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
Abstract Number: 0445 • ACR Convergence 2024
Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Liya Stolyar¹, Sadaf Sediqi², Richard Lafayette³, Maurice Druzin⁴, Saadiya Hawa⁵, Amanda Moyer⁶, Yashaar Chaichian² and Julia Simard², ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶Stanford University, San Bruno, CA
Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
Abstract Number: 0369 • ACR Convergence 2024
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Simonetta van Griethuysen¹, Quirine Dumoulin² and Annette van der Helm-van Mil³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
Abstract Number: 0413 • ACR Convergence 2024
Efficacy of Intra-articular Glucocorticoids as a Treatment for Oligoarticular Juvenile Idiopathic Arthritis: A Bicentric Retrospective Study in Japan
Keiji Akamine¹, Mao Mizuta², Reiko Yatabe¹, Yukari Aida³, Naoaki Mikami¹, Ryoko Harada¹, Riku Hamada¹, Yasuo Nakagishi³ and Hiroshi Hataya¹, ¹Department of Nephrology and Rheumatology, Tokyo Metropolitan Children’s Medical Center, Fuchu, Tokyo, Japan, ²Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kanazawa, Hyogo, Japan, ³2) Department of Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Hyogo, Japan
Background/Purpose: Intra-articular glucocorticoids (IAGCs), a treatment for oligoarticular JIA, is a local therapy that obviates the need for systemic medication and its attendant side effects…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0383 • ACR Convergence 2024
Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State
Ilaria Maccora¹, hermine brunner², Mekibib Altaye³, Alexandra Duell³, Wendy Haffey⁴, Megan Quinlan-Waters³, Alyssa Sproles⁵, Sherry Thornton⁵, Virginia Miraldi Utz³, Kenneth Greis⁴ and sheila Angeles-Han⁶, ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
Abstract Number: 0391 • ACR Convergence 2024
Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Marc Natter², Laura Schanberg³ and Yukiko Kimura⁴, and CARRA Registry Investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Boston Children's Hospital, Boston, MA, ³Duke University Medical Center, DURHAM, NC, ⁴Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Optimizing treatment of JIA continues to be a challenge. Biologic DMARD (bDMARD) therapies have significantly improved outcomes but is costly, may be more difficult…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].